Transgenic mouse model reveals an unsuspected role of the acetylcholine receptor in statin-induced neuromuscular adverse drug reactions

Pharmacogenomics Journal

Volumn 13, Issue 4, 2013, Pages 362-368

  Grajales Reyes, G E ^a   Baez Pagan C A ^a,b   Zhu, H ^c   Grajales Reyes, J G ^a   Delgado Velez M ^a   Garcia Beltran W F ^a   Luciano, C A ^b,d   Quesada, O ^a,b   Ramirez R ^a   Gomez C M ^c   Lasalde Dominicci, J A ^a,b  

^a UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^b Myo ADR Technologies Corp   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

Author keywords

Adverse drug reactions; Cholesterol; Neuromuscular junction; Nicotinic acetylcholine receptor; Statins

Indexed keywords

ATORVASTATIN; CASPASE; CAVEOLIN 1; CHOLINERGIC RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ORGANIC ANION TRANSPORTER 2;

ADVERSE OUTCOME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONGENITAL MYASTHENIC SYNDROME; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVATION; GENE; GENE FREQUENCY; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC CODE; MOUSE; NERVE ENDING; NEUROMUSCULAR DISEASE; NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA SUBUNIT GENE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SLCO1B1 GENE; TRANSGENIC MOUSE;

MUS; MUS MUSCULUS;

EID: 85041137161     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2012.21     Document Type: Article

References (47)

1. Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes III J. Factors of risk in the development of coronary heart disease-six year follow-up experience. The Framingham Study. Ann Intern Med 1961; 55: 33-50.
2. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 2011; 123: e18-209.
3. Brautbar A, Ballantyne CM. Pharmacological strategies for lowering LDL cholesterol: statins and beyond. Nat Rev Cardiol 2011; 8: 253-265.
4. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90. 056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
5. Haukka J, Niskanen L, Partonen T, Lönnqvist J, Tiihonen J. Statin usage and allcause and disease-specific mortality in a nationwide study. Pharmacoepidemiology and Drug Safety 2012; 21: 61-69.
6. Fernandez G, Spatz ES, Jablecki C, Phillips PS. Statin myopathy: a common dilemma not reflected in clinical trials. Cleve Clin J Med 2011; 78: 393-403.
7. Tomaszewski M, Stêpieñ KM, Tomaszewska J, Czuczwar SJ. Statin-induced myopathies. Pharmacol Rep 2011; 63: 859-866.
8. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002; 346: 539-540.
9. Vladutiu GD. Genetic predisposition to statin myopathy. Curr Opin Rheumatol 2008; 20: 648-655.
10. Mangravite LM, Thorn CF, Krauss RM. Clinical implications of pharmacogenomics of statin treatment. Pharmacogenomics J 2006; 6: 360-374.
11. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med 2008; 359: 789-799.
12. Ruaño G, Thompson PD, Windemuth A, Seip RL, Dande A, Sorokin A et al. Physiogenomic association of statin-related myalgia to serotonin receptors. Muscle Nerve 2007; 36: 329-335.
13. Ruaño G, Thompson PD, Windemuth A, Smith A, Kocherla M, Holford TR et al. Physiogenomic analysis links serum creatine kinase activities during statin therapy to vascular smooth muscle homeostasis. Pharmacogenomics 2005; 6: 865-872.
14. Brunham LR, Lansberg PJ, Zhang L, Miao F, Carter C, Hovingh GK et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. The Pharmacogenomics J advance online publication, 18. January 2011; doi:10.1038/tpj.2010.92.
15. Marciante KD, Durda JP, Heckbert SR, Lumley T, Rice K, McKnight B et al. Cerivastatin, genetic variants, and the risk of rhabomyolysis. Pharmacogenet Genomics 2011; 21: 280-288.
16. Karlin A. Emerging structure of the nicotinic acetylcholine receptors. Nat Rev Neurosci 2002; 3: 102-114.
17. Corringer PJ, Le Novère N, Changeux JP. Nicotinic receptors at the amino acid level. Annu Rev Pharmacol Toxicol 2000; 40: 431-458.
18. Le Novè re N, Corringer P-J, Changeux J-P. The diversity of subunit composition in nAChRs: evolutionary origins, physiologic and pharmacologic consequences. J Neurobiol 2002; 53: 447-456.
19. Engel AG, Shen X-M, Selcen D, Sine SM. What have we learned from the congenital myasthenic syndromes. J Mol Neurosci 2010; 40: 143-153.
20. Otero-Cruz JD, Báez-Pagán CA, Dorna-Pérez L, Grajales-Reyes GE, Rami{dotless}́rez-Ordoñez RT, Luciano CA et al. Decoding pathogenesis of slow-channel congenital myasthenic syndromes using recombinant expression and mice models. P R Health Sci J 2010; 29: 4-17.
21. Burger K, Gimpl G, Fahrenholz F. Regulation of receptor function by cholesterol. Cell Mol Life Sci 2000; 57: 1577-1592.
22. Fong TM, McNamee MG. Correlation between acetylcholine receptor function and structural properties of membranes. Biochemistry 1986; 25: 830-840.
23. Guzmán GM, Ortiz-Acevedo A, Santiago J, Rojas LV, Lasalde-Dominicci JA. Regulation of acetylcholine receptor function by cholesterol. In: Recent Res Devel Membrane Biol. Research Signpost: India, 2002, pp 127-146.
24. Santiago J, Guzmàn GR, Rojas LV, Marti R, Asmar-Rovira GA, Santana LF et al. Probing the effects of membrane cholesterol in the Torpedo californica acetylcholine receptor and the novel lipid-exposed mutation alpha C418W in Xenopus oocytes. J Biol Chem 2001; 276: 46523-46532.
25. Gomez CM, Maselli R, Gundeck JE, Chao M, Day JW, Tamamizu S et al. Slowchannel transgenic mice: a model of postsynaptic organellar degeneration at the neuromuscular junction. J Neurosci 1997; 17: 4170-4179.
26. Gomez CM, Maselli RA, Groshong J, Zayas R, Wollmann RL, Cens T et al. Active calcium accumulation underlies severe weakness in a panel of mice with slowchannel syndrome. J Neurosci 2002; 22: 6447-6457.
27. Vohra BPS, Groshong JS, Maselli RA, Verity MA, Wollmann RL, Gomez CM. Focal caspase activation underlies the endplate myopathy in slow-channel syndrome. Ann Neurol 2004; 55: 347-352.
28. Vohra BPS, Groshong JS, Zayas R, Wollmann RL, Gomez CM. Activation of apoptotic pathways at muscle fiber synapses is circumscribed and reversible in a slow-channel syndrome model. Neurobiol Dis 2006; 23: 462-470.
29. Groshong JS, Spencer MJ, Bhattacharyya BJ, Kudryashova E, Vohra BPS, Zayas R et al. Calpain activation impairs neuromuscular transmission in a mouse model of the slow-channel myasthenic syndrome. J Clin Invest 2007; 117: 2903-2912.
30. Báez-Pagán CA, Marti{dotless}́nez-Ortiz Y, Otero-Cruz JD, Salgado-Villanueva IK, Velázquez G, Ortiz-Acevedo A et al. Potential role of caveolin-1-positive domains in the regulation of the acetylcholine receptor's activatable pool: implications in the pathogenesis of a novel congenital myasthenic syndrome. Channels (Austin) 2008; 2: 180-190.
31. Lardizabal JA, Deedwania PC. Benefits of statin therapy and compliance in high risk cardiovascular patients. Vasc Health Risk Manag 2010; 6: 843-853.
32. Jacobson TA. Toward 'pain-free' statin prescribing: clinical algorithm for diagnosis and management of myalgia. Mayo Clin Proc 2008; 83: 687-700.
33. Altshuler D, Daly MJ, Lander ES. Genetic mapping in human disease. Science 2008; 322: 881-888.
34. Hirschhorn JN, Gajdos ZKZ. Genome-wide association studies: results from the first few years and potential implications for clinical medicine. Annu Rev Med 2011; 62: 11-24.
35. Cannon TD. Candidate gene studies in the GWAS era: the MET proto-oncogene, neurocognition, and schizophrenia. Am J Psychiatry 2010; 167: 369-372.
36. Amos W, Driscoll E, Hoffman JI. Candidate genes versus genome-wide associations: which are better for detecting genetic susceptibility to infectious disease? Proc Biol Sci 2011; 278: 1183-1188.
37. Johansen CT, Wang J, Lanktree MB, Cao H, McIntyre AD, Ban MR et al. Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nat Genet 2010; 42: 684-687.
38. Kwon JM, Goate AM. The candidate gene approach. Alcohol Res Health 2000; 24: 164-168.
39. Couvert P, Chapman MJ, Carrié A. Impact of genetic variation in the SLCO1B1 gene on statin efficacy in low-density lipoprotein cholesterol-lowering therapy. Pharmacogenomics 2011; 12: 137-139.
40. Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA et al. The SLCO1B15 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009; 54: 1609-1616.
41. Gomez CM, Bhattacharyya BB, Charnet P, Day JW, Labarca C, Wollmann RL et al. A transgenic mouse model of the slow-channel syndrome. Muscle Nerve 1996; 19: 79-87.
42. Williams TM, Lisanti MP. The caveolin proteins. Genome Biol 2004; 5: 214.
43. Lajoie P, Nabi IR. Lipid rafts, caveolae, and their endocytosis. Int Rev Cell Mol Biol 2010; 282: 135-163.
44. Murata M, Peränen J, Schreiner R, Wieland F, Kurzchalia TV, Simons K. VIP21/caveolin is a cholesterol-binding protein. Proc Natl Acad Sci USA 1995; 92: 10339-10343.
45. Chang WJ, Rothberg KG, Kamen BA, Anderson RG. Lowering the cholesterol content of MA104 cells inhibits receptor-mediated transport of folate. J Cell Biol 1992; 118: 63-69.
46. Shen X-M, Deymeer F, Sine SM, Engel AG. Slow-channel mutation in acetylcholine receptor alphaM4 domain and its efficient knockdown. Ann Neurol 2006; 60: 128-136.
47. Meador BM, Huey KA. Statin-associated myopathy and its exacerbation with exercise. Muscle Nerve 2010; 42: 469-479.